

4th Annual Early Detection Research Network (EDRN) Scientific Workshop, Philadelphia, PA

Poster Session

*Tuesday, March 22, 2006
3:30 – 5:30 p.m.*

*Poster Highlights
5:30 – 6:30 p.m.*

Chairs

Dean Brenner, M.D., University of Michigan

David Sidransky, M.D., Johns Hopkins University School of Medicine

Posters/Presenters

1. Biomarker Discovery and Validation for Patient Selection Using Microdissected Tumor Tissues Brian M. Balgley, Ph.D., Calibrant Biosystems
2. Haptoglobin- A Potential Serum Tumor Bio-Marker in Small Cell Lung CancerAjit Bharti, Ph.D., Boston University School of Medicine
3. Automated Peak Picking and Alignment of TOF-MS Data for Biomarker Discovery and Early Cancer Diagnosis Christine Bunai, Ph.D., College of William and Mary
4. TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer Arul Chinnaiyan, M.D., Ph.D., University of Michigan
5. Standard Specimen Sets for Assessing Cancer Biomarkers in Women Daniel Cramer, M.D., Sc.D., Brigham and Women's Hospital
6. Use of a Monoclonal Antibody Against Human Mucin 9 for Immuno-Histochemical Studies of Oviductin Expression in Fallopian Tubes and Serous Ovarian Cancer Daniel Cramer, M.D., Sc.D., Brigham and Women's Hospital
7. Novel Strategies for MALDI-TOF Profiling of Low Abundance Proteins in Human Serum Richard Drake, Ph.D., Eastern Virginia Medical School
8. Serum Glycoprotein Biomarker Discovery for Prostatic Disease Using Differential Lectin Capture Strategies Richard Drake, Ph.D., Eastern Virginia Medical School

9. Enhanced Detection of Low Abundance Human Plasma Proteins by Immunodepletion of 20 Abundant Proteins
Lynn A. Echan, B.S., The Wistar Institute
10. Prevalence of High Level Overexpression of Candidate Biomarkers for Non-Small Cell Lung Carcinoma (NSCLC) Confirmed by qRT-PCR
Wilbur A. Franklin, M.D., University of Colorado Health Science Center
11. Electrochemiluminescent Multiplexed Measurement of Biomarkers: Current Applications in Research and Future Applications in the Clinic
Eli Glezer, Ph.D., Meso Scale Diagnostics
12. Direct Biomarker Concentration Measurements in Serum Using Carbon Nanotube Capacitor Chips
Lee Goodglick, Ph.D., University of California at Los Angeles
13. Na,K-ATPase as a Cancer Biomarker: Implication in Cancer Progression and Prognosis
Lee Goodglick, Ph.D., University of California at Los Angeles
14. The Use of Paraffin Embedded Tissues in Analyses Using Real Time Quantitative PCR
William Grizzle, M.D., Ph.D., University of Alabama at Birmingham
15. Genetic Profiling by Solid Phase Gene Extraction
K.H. Hasenstein, Ph.D., University of Louisiana
16. Printed Glycan Array Identifies Specific Signatures of Anti-Glycan Autoantibodies as Biomarkers in Sera of Breast Cancer Patients: Diagnostic, Prognostic And Therapeutic Opportunities
Margaret E. Huflejt, Ph.D., GlycoMedical Research Institute
17. Novel Domain-Specific Anti-MUC4 Antibodies: New Tools for the Diagnosis of Pancreatic Cancer
Maneesh Jain, Ph.D., University of Nebraska Medical Center
18. Use of Random Fine Needle Aspiration to Measure RNA Expression of Steroidogenic Enzymes in the Breast
Seema Khan, M.D., Northwestern University
19. A Functional Genomic Approach to Biomarker Discovery in Pancreatic Cancer
Ann M. Killary, Ph.D., University of Texas MD Anderson Cancer Center
20. Diagnosis of Breast Cancer Based on DNA Methylation Profile
Victor V. Levenson, M.D., Ph.D., Feinberg School of Medicine, Northwestern University
21. Cancer Cell Type-Specific Transcriptomes for Biomarker Discovery
Alvin Y. Liu, Ph.D., University of Washington
22. DNA Repair Biomarkers for Cancer Risk Assessment and Early Detection
Zvi Livneh, Ph.D., Weizmann Institute

23. Biomarker-Based Telecytopathology: A New Prospective for Global Cervical Cancer Control
Nenad Markovic, M.D., Ph.D., BioSciCon, Inc
24. Circulating Markers for Breast Cancer Discrimination Assayed by Luminex®
Jeffrey Marks, Ph.D., Duke University
25. Hypermethylation of the MAL Gene Promoter in Breast Cancer
Jeffrey Marks, Ph.D., Duke University
26. A Suite of Assays to Detect Phosphorylated Receptor Tyrosine Kinases Associated with Neoplasia
Anu Mathew, Ph.D., Meso Scale Discovery
27. Inactivation and Restoration of Transforming Growth Factor-Beta Signaling Modulated Hepatocellular Carcinogenesis in Hepatocellular Cancer Cell Lines and *elf*^{+/-} tissues
Lopa Mishra, M.D., Georgetown University
28. TGF-Beta/Smads Regulate a Wide Variety of Biological Responses through Transcriptional Regulation of Target Genes
Lopa Mishra, M.D., Georgetown University
29. Transforming Growth Factor-Beta Suppresses Nonmetastatic Colon Cancer through Smad4 and Adaptor Protein ELF at an Early Stage of Tumorigenesis
Lopa Mishra, M.D., Georgetown University
30. RTPCR Detection of Cancer Cells in Blood Based on Presence of a tNOX Splice Variant mRNA
D. James Morre, Ph.D., NOX Technologies/Purdue University
31. tNOX a Circulating Pancancer Marker Potentially Indicative of Cancer Presence
D. James Morre, Ph.D., NOX Technologies/Purdue University
32. Deletions of the *TSPY* Gene Cluster in Prostate Cancer
Susan L. Naylor, Ph.D., University of Texas Health Sciences Center at San Antonio
33. Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study
Susan L. Naylor, Ph.D., University of Texas Health Science Center at San Antonio
34. Recurrent Homozygous Deletion on Chromosome 18q22.3 in Prostate Cancer
Susan L. Naylor, Ph.D., University of Texas Health Science Center at San Antonio

35. The VEGF +405 CC Polymorphism Is Associated with Prostate Cancers of Poor Prognosis
Susan L. Naylor, Ph.D., University of Texas Health Science Center at San Antonio
36. Variants of Semaphorin 3F Are Associated with Prostate Cancer Prognosis
Susan Naylor, Ph.D., University of Texas Health Science Center at San Antonio
37. The Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer
Susan L. Naylor, Ph.D., University of Texas Health Science Center at San Antonio
38. Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Susan Naylor, Ph.D., University of Texas Health Science Center at San Antonio
39. Heterogeneity in HPV 16 DNA Methylation Assessed by Pyrosequencing
Mangalathu Rajeevan, Ph.D., Center for Disease Control and Prevention
40. Characterization of Telomerase-Immortalized Primary Non-Malignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Cultures
Johng Rhim, M.D., Center for Prostate Disease Research
41. Prediction Models for Recurrence and Survival Following Surgery in Stage IA and IB NSCLC
William Rom, M.D., M.P.H., New York University
42. Esophageal Adenocarcinoma and Barrett's Esophagus Clinical Data, Blood and Tissue Bank
Yvonne Romero, M.D., Mayo Clinic
43. Identifying Molecular Signatures of Indolent and Aggressive Prostate Cancer
Mark A. Rubin, M.D., Brigham and Women's Hospital
44. Peptide-Linked Nanodevices for Biomarker Detection
Steven S. Smith, Ph.D., City of Hope
45. Comprehensive DNA Methylation Mapping from Trace Human Specimens
Simon D. Spivack, M.D., Wadsworth Center for Laboratories and Research
46. Development of Multiplexed Immunoassay Panels for Human Growth Factors and Growth Factor Receptors: bFGF, sFlt-1, PlGF, VEGF, KDR and c-Kit
Martin Stengelin, Ph.D., Meso Scale Discovery

47. Chromoendoscopic Colonoscopy Detects More Adenomas than Conventional Colonoscopy: A Randomized Trial of Back-to-Back Colonoscopies
Elena M. Stoffel, M.D., M.P.H., Brigham and Women's Hospital
48. Incidence of Detecting Mutated K-ras DNA in Urine, Plasma and Serum from Patients with Carcinoma or Adenomatous Polyps
Ying-Hsiu Su, Ph.D., Drexel University College of Medicine
49. Early Detection of Breast Cancer Using High-throughput Cloning of Tumor Antigens and Detection on Protein Microarrays
Michael Tainsky, Ph.D., Karmanos Cancer Center
50. Discovering Low Abundance Cancer Biomarkers: Balancing Depth of Coverage with Throughput and Confidence of Protein Assignment
Hsin-Yao Tang, Ph.D., Wistar Institute
51. Pattern Detection and Cancer Diagnosis in Adult T-cell Leukemia Patients
Eugene Tracy, Ph.D., College of William and Mary
52. Evaluation of Gene Expression Biomarkers for Cervical Intraepithelial Neoplasia
Elizabeth Unger, M.D., Ph.D., Centers for Disease Control and Prevention
53. Development of a Multiplexed DNA Methylation Assay for Prostate Cancer Detection
Shobha Varde, M.S., Veridex, LLC
54. Chromosomal Aneusomy Detected by FISH in Sputum Predicts for Lung Cancer in Case-Control Study
Marileila Varella-Garcia, Ph.D., University of Colorado Health Science Center
55. Structural and Numerical Chromosomal Abnormalities in Bronchial Cells from Heavy Smokers
Marileila Varella-Garcia, Ph.D., University of Colorado Health Sciences Center
56. Improved Prediction of PSA Biochemical Recurrence by Quantitative Nuclear Grade (QNG) Signature Compared to Pathology Findings Post-prostatectomy
Robert W. Veltri, Ph.D., Johns Hopkins University School of Medicine
57. Quantitative Nuclear Morphometry Characterizes Differences in Feulgen Stained Nuclei Captured by Image Analysis from Primary Gleason Grading Patterns
Robert W Veltri, Ph.D., Johns Hopkins University School of Medicine
58. Study Uptake in EDRN High Risk Registrants
Patrice Watson, Ph.D., Creighton University

59. Metrology for Cancer Biomarker: Affinity Analysis of Human HER2 with IgY
Yan Xiao, Ph.D., National Institute of Standards and Technology (NIST)
60. An Ultrasensitive FACTT Assay to Detect Melanoma Associated Biomarkers in Serum
Xiaowei Xu, M.D., University of Pennsylvania
61. ProMAT: A Bioinformatics Tool for Rapid Analysis of ELISA Microarray Data
Richard C. Zangar, Ph.D., Pacific Northwest National Laboratory

Additional Posters:

62. Quantitative End-Point LATE-PCR Assays for Detection of LOH as a Biomarker
J. Aquiles Sanchez, Ph.D., Brandeis University
63. KrasG12D, Cox-2 and Oxidative Stress
Gina DeNicola, University of Pennsylvania
64. Randox Laboratories Limited
John Lamont, M.Sc., Randox Laboratories Limited